BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Keytruda Qlex (Pembrolizumab berahyaluronidase alfa) readouts 
 · AssetMemo
X-WR-CALDESC:Upcoming readouts of Keytruda Qlex (Pembrolizumab berahyaluron
 idase alfa)\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06041802-2259@assetmemo.bio
DTSTAMP:20261121T010640Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Keytruda Qlex (Pembrolizumab berahyaluronidase alfa): Phase 2 reado
 ut est. (NCT06041802)
DESCRIPTION:Keytruda Qlex (Pembrolizumab berahyaluronidase alfa)\, phase 2.
 \nStudy: A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (P
 embrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese
  Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcino
 ma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)\nE
 stimated primary completion: 31 March 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pembrolizumab-berahyaluronidase-alfa#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06041802
URL:https://assetmemo.bio/drug/pembrolizumab-berahyaluronidase-alfa#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07919899-2259@assetmemo.bio
DTSTAMP:20261121T010640Z
DTSTART;VALUE=DATE:20280502
DTEND;VALUE=DATE:20280503
SUMMARY:Keytruda Qlex (Pembrolizumab berahyaluronidase alfa): Phase 3 reado
 ut est. (NCT07919899)
DESCRIPTION:Keytruda Qlex (Pembrolizumab berahyaluronidase alfa)\, phase 3.
 \nStudy: Pharmacokinetics\, Immunogenicity and Safety of Subcutaneous Dupi
 lumab and Berahyaluronidase Alfa (ALT-B4) Coformulation\nEstimated primary
  completion: 2 May 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/pembrolizumab-berahyaluronidase-alfa#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07919899
URL:https://assetmemo.bio/drug/pembrolizumab-berahyaluronidase-alfa#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06504394-2259@assetmemo.bio
DTSTAMP:20261121T010640Z
DTSTART;VALUE=DATE:20281108
DTEND;VALUE=DATE:20281109
SUMMARY:Keytruda Qlex (Pembrolizumab berahyaluronidase alfa): Phase 2 reado
 ut est. (NCT06504394)
DESCRIPTION:Keytruda Qlex (Pembrolizumab berahyaluronidase alfa)\, phase 2.
 \nStudy: A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-
 3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants 
 With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed
  or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475
 A-F65)\nEstimated primary completion: 8 November 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pembrolizumab-berahyaluronidase-alfa#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0650439
 4
URL:https://assetmemo.bio/drug/pembrolizumab-berahyaluronidase-alfa#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07190248-2259@assetmemo.bio
DTSTAMP:20261121T010640Z
DTSTART;VALUE=DATE:20291207
DTEND;VALUE=DATE:20291208
SUMMARY:Keytruda Qlex (Pembrolizumab berahyaluronidase alfa): Phase 3 reado
 ut est. (NCT07190248)
DESCRIPTION:Keytruda Qlex (Pembrolizumab berahyaluronidase alfa)\, phase 3\
 , Non-Small Cell Lung Cancer.\nStudy: A Clinical Study of Calderasib (MK-1
 084) and Other Treatments for Participants With Non-Small Cell Lung Cancer
  (MK-1084-007/KANDLELIT-007)\nEstimated primary completion: 7 December 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab-bera
 hyaluronidase-alfa#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07190248
URL:https://assetmemo.bio/drug/pembrolizumab-berahyaluronidase-alfa#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07750158-2259@assetmemo.bio
DTSTAMP:20261121T010640Z
DTSTART;VALUE=DATE:20300405
DTEND;VALUE=DATE:20300406
SUMMARY:Keytruda Qlex (Pembrolizumab berahyaluronidase alfa): Phase 3 reado
 ut est. (NCT07750158)
DESCRIPTION:Keytruda Qlex (Pembrolizumab berahyaluronidase alfa)\, phase 3\
 , Colorectal Cancer.\nStudy: Zanzalintinib Alone or in Combination With Pe
 mbrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Can
 cer With Molecular Residual Disease\nEstimated primary completion: 5 April
  2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab-
 berahyaluronidase-alfa#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07750158
URL:https://assetmemo.bio/drug/pembrolizumab-berahyaluronidase-alfa#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07829783-2259@assetmemo.bio
DTSTAMP:20261121T010640Z
DTSTART;VALUE=DATE:20311117
DTEND;VALUE=DATE:20311118
SUMMARY:Keytruda Qlex (Pembrolizumab berahyaluronidase alfa): Phase 3 reado
 ut est. (NCT07829783)
DESCRIPTION:Keytruda Qlex (Pembrolizumab berahyaluronidase alfa)\, phase 3\
 , Bladder Cancer.\nStudy: A Clinical Trial of Sacituzumab Tirumotecan (Sac
 -TMT\, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder 
 Cancer (MK-2870-055)\nEstimated primary completion: 17 November 2031. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab-berahyaluro
 nidase-alfa#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07829783
URL:https://assetmemo.bio/drug/pembrolizumab-berahyaluronidase-alfa#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07513376-2259@assetmemo.bio
DTSTAMP:20261121T010640Z
DTSTART;VALUE=DATE:20340822
DTEND;VALUE=DATE:20340823
SUMMARY:Keytruda Qlex (Pembrolizumab berahyaluronidase alfa): Phase 3 reado
 ut est. (NCT07513376)
DESCRIPTION:Keytruda Qlex (Pembrolizumab berahyaluronidase alfa)\, phase 3\
 , Non-Small Cell Lung Cancer.\nStudy: A Clinical Trial of Adjuvant Intisme
 ran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronida
 se Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-0
 14)\nEstimated primary completion: 22 August 2034. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/pembrolizumab-berahyaluronidase-alfa#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07513376
URL:https://assetmemo.bio/drug/pembrolizumab-berahyaluronidase-alfa#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03486873-2259@assetmemo.bio
DTSTAMP:20261121T010640Z
DTSTART;VALUE=DATE:20430804
DTEND;VALUE=DATE:20430805
SUMMARY:Keytruda Qlex (Pembrolizumab berahyaluronidase alfa): Phase 3 reado
 ut est. (NCT03486873)
DESCRIPTION:Keytruda Qlex (Pembrolizumab berahyaluronidase alfa)\, phase 3\
 , Solid Tumors.\nStudy: Long-term Safety and Efficacy Extension Study for 
 Participants With Advanced Tumors Who Are Currently on Treatment or in Fol
 low-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)\nEstim
 ated primary completion: 4 August 2043. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pembrolizumab-berahyaluronidase-alfa#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT03486873
URL:https://assetmemo.bio/drug/pembrolizumab-berahyaluronidase-alfa#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
